Clozapine plasma level monitoring: Current status

Psychiatric Quarterly

Volumn 67, Issue 4, 1996, Pages 297-311

  Cooper, Thomas B ^a,b,c  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b The New York Presbyterian Hospital

^c NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

BLOOD; DOSE RESPONSE; DRUG INTERACTION; DRUG MONITORING; HUMAN; PHYSIOLOGY; REVIEW; RISK FACTOR; SCHIZOPHRENIA; STANDARD;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG MONITORING; HUMANS; RISK FACTORS; SCHIZOPHRENIA;

EID: 0030345624     PISSN: 00332720     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02326373     Document Type: Article

References (73)

1. Gerson SL, Arce C, and Meltzer HY: N-desmethylclozapine: a clozapine metabolite that suppresses haemopoiesis. British Journal of Haematology 86: 555-561, 1994.
2. Wolkin A, Brodie JD, Barouche F, et al: Dopamine receptor occupancy and plasma haloperidol levels. Archives of General Psychiatry 46: 482-483, 1989.
3. Karbe HK, Wienhard K, Hamacher M, et al: Positron emission tomography with (18F)methylspiperone demonstrates D2 dopamine receptor binding differences of clozapine and haloperidol. Journal of Neural Transmission 86: 163-173, 1991.
4. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Archives of General Psychiatry 49: 538-544, 1992.
5. Haase HJ: Extrapyramidal modification of fine movements - a "conditio sine qua non" of the fundamental therapeutic action of neuroleptic drugs. In: Bordeleau J (Ed) Extrapyramidal System and Neuroleptics. Edition Psychiatriques, Montreal. pp. 329-353, 1961.
6. McEvoy JP, Hogarty GE, and Steingard S: Optimal dose of neuroleptic in acute schizophrenia: A controlled study of the neuroleptic threshold and higher haloperidol dose. Archives of General Psychiatry 48: 739-745, 1991.
7. 4 receptor varies with the affinity of the competing radioligand. European Journal of Pharmacology 291: 59-66, 1995.
8. Van Tol HHM, Bunzow JR, Guan HC, et al: Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350: 610-614, 1991.
9. Seeman P: Dopamine receptor sequences: Therapeutic levels of neuroleptic occupancy D2 receptors, clozapine occupies D4. Neuropsychopharmacology 7: 261-284, 1992.
10. 2 receptor occupancy in relation to clozapine serum concentration: A PET study of schizophrenic patients. American Journal of Psychiatry 152: 1444-1449, 1995.
11. Richelson E: Neuroleptic affinities for human brain receptors and their use in predicting adverse effects. Journal of Clinical Psychiatry 45: 331-336, 1984.
12. Fischer V, Vogels B, Maurer G, et al: The antipsychotic clozapine in metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. The Journal of Pharmacology and Experimental Therapeutics 260: 1355-1360, 1992.
13. Dahl M-L, Llerena A, Bondesson U, et al: Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. British Journal of Clinical Pharmacology 37: 71-74, 1994.
14. Pirmohamed M, Williams D, Madden S, et al: Metabolism and bioactivation of clozapine by human liver in vitro. The Journal of Pharmacology and Experimental Therapeutics 272: 984-990, 1995.
15. Bertilsson L, Carrillo JA, Dahl M-L, et al: Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. British Journal of Clinical Pharmacology 38: 471-473, 1994.
16. Jerling M, Lindstrom L, Bondesson U, et al: Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: Evidence from a therapeutic drug monitoring service. Therapeutic Drug Monitoring 16: 368-374, 1994.
17. Brosen K, Skjelbo E, Rasmussen BB, et al: Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochemical Pharmacology 45: 1211-1214, 1993.
18. Arranz MJ, Dawson E, Shaikh S, et al: Cytochrome P4502D6 genotype does not determine response to clozapine. British Journal of Clinical Pharmacology 39: 417-420, 1995.
19. Gauch R, and Michaelis W: The metabolism of 8-chloro-11(4-methyl-1-piperazinyl)-5H-dibenzo(b,e)(1,4)diazepine (clozapine) in mice, dogs and human subjects. FarmacoEdizione Pratica 26: 667-681, 1971.
20. Meier J: Bioanalytical assay of clozapine and its N-oxide metabolite and the determination of their blood levels in the dog. Proceedings of the British Pharmacological Society, January 8-10, 1975.
21. Jann MW, Lam YWF, and Chang W-H: Rapid formation of clozapine in guinea-pigs and man following clozapine-N-oxide administration. Archives of International Pharmacodynamics 328: 243-250, 1994.
22. Choc MG, Hsuan F, Honigfeld G, et al: Single- vs multiple-dose pharmacokinetics of clozapine in psychiatric patients. Pharmaceutical Research 7: 347-351, 1990.
23. Haring C, Barnas C, Saria A, et al: Dose-related plasma levels of clozapine. Journal of Clinical Psychopharmacology 9: 71-72, 1989.
24. Oyewumi LK, Freeman DJ, and Vollick D: Can low-dose clozapine pharmacokinetics predict steady-state plasma concentration? Therapeutic Drug Monitoring 17: 137-141, 1995.
25. +-glucuronide in the urine of patients treated with clozapine using electrospray mass spectrometry. Biological Mass Spectrometry 23: 147-148, 1994.
26. Zeren W, Minglian L, Peipei X, et al: Determination of clozapine and its metabolites in serum and urine by reversed phase HPLC. Biomedical Chromatography 1: 53-57, 1986.
27. Haring C, Humpel C, Auer B, et al: Clozapine plasma levels determined by high-performance liquid chromatography with ultraviolet detection. Journal of Chromatography 428: 160-166, 1988.
28. Lovdahl MJ, Perry PJ, and Miller DD: The assay of clozapine and N-desmethylclozapine in human plasma by high-performance liquid chromatography. Therapeutic Drug Monitoring 13: 69-72, 1991.
29. Chovan JP and Vermeulen JD: High-performance liquid chromatographic method for a clozapine analogue, CGS 13429, and its N-oxide and desmethyl metabolites. Journal of Chromatography 494: 413-419, 1989.
30. Weigmann H, and Hiemke C: Determination of clozapine and its major metabolites in human serum using automated solid-phase extraction and subsequent isocratic high- performance liquid chromatography with ultraviolet detection. Journal of Chromatography 583: 209-216, 1992.
31. Volpicelli SA, Centorrino F, Puopolo PR, et al: Determination of clozapine, norclozapine, and clozapine-N-oxide in serum by liquid chromatography. Clinical Chemistry 39: 1656-1659, 1993.
32. Olesen OV and Poulsen B: On-line fully automated determination of clozapine and desmethylclozapine in human serum by solid-phase extraction on exchangeable cartridges and liquid chromatography using a methanol buffer mobile phase on unmodified silica. Journal of Chromatography 622: 39-46, 1993.
33. Chung M-C, Lin S-K, and Chang W-H: Determination of clozapine and desmethylclozapine in human plasma by high-performance liquid chromatography with ultraviolet detection. Journal of Chromatography 613: 168-173, 1993.
34. McCarthy PT, Hughes S, and Paton C: Measurement of clozapine and norclozapine in plasma/serum by high performance liquid chromatography with ultraviolet detection. Biomedical Chromatography 9: 36-41, 1995.
35. Fadiran EO, Leslie J, Fossler M, et al: Determination of clozapine and its major metabolites in human serum and rat plasma by liquid chromatography using solid-phase extraction and ultraviolet detection. Journal of Pharmaceutical and Biomedical Analysis 13: 185-190, 1995.
36. Jennison TA, Brown P, and Crossett J: A rapid gas chromatographic method quantitating clozapine in human plasma or serum for the purpose of therapeutic monitoring. Journal of Analytical Toxicology 19: 537-541, 1995.
37. Heipertz R, Pilz H, and Beckers W: Serum concentrations of clozapine determined by nitrogen selective gas chromatography. Archives of Toxicology 37: 313-318, 1977.
38. Richter K: Determination of clozapine in human serum by capillary gas chromatography. Journal of Chromatography 434: 465-468, 1988.
39. Bondesson U and Lindstrom LH: Determination of clozapine and its N-demethylated metabolite in plasma by use of gas chromatography-mass spectrometry with single ion detection. Psychopharmacology 95: 472-475, 1988.
40. Rosenthaler J, Nimmerfall F, Sigrist R, et al: Non-equilibrium method for the radioimmunoassay of clozapine in the presence of metabolites. European Journal of Biochemistry 80: 603-609, 1977.
41. Lin G, McKay G, Hubbard JW, et al.: Decomposition of clozapine N-oxide in the qualitative and quantitative analysis of clozapine and its metabolites. Journal of Pharmaceutical Sciences 83: 1412-1417, 1994.
42. Markowitz JS and Patrick KS: Thermal degradation of clozapine-N-oxide to clozapineduring gas chromatographic analysis. Journal of Chromatography B: Biomedical Applications 668: 171-174, 1995.
43. Thorup M and Fog R: Clozapine treatment of schizophrenic patients: plasma concentration and coagulation factors. Acta Psychiatr Scand 55: 123-126, 1977.
44. Ackenheil M, Brau H, Burkhart A, et al: Antipsychotische wirksamkeit im werhaltnis zum plasmaspiegel von clozapin. Arzneimittelforschung 26: 1156-1158, 1976.
45. Brau VH, Burkhart A, Packa W, et al: Zenziehungen zwischen Wirkungen und plasmasspiegel von clozapin. Arzneimittelforschung 1300-1301, 1978.
46. Perry PJ, Miller DD, Arndt SV, et al: Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. American Journal of Psychiatry 148: 231-235, 1991.
47. Miller DD, Fleming F, Holman TL, et al: Plasma clozapine concentrations as a predictor of clinical response: A follow-up study. Journal of Clinical Psychiatry 55: 117-121, 1994.
48. Kronig MH, Munne RA, Szymanski S, et al: Plasma clozapine levels and clinical raesponse for treatment-refractory schizophrenic patients. American Journal of Psychiatry 152: 179-182, 1995.
49. Potkin SG, Bera R, Gulasekaram B, et al: Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. Journal of Clinical Psychiatry 55: 133-136, 1994.
50. Hasegawa M, Gutierrez-Esteinou R, Way L, et al: Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. Journal of Clinical Psychopharmacology 13: 383-390, 1993.
51. Gu NF: Pharmacokinetic study of clozapine. Chinese Journal of Neurology and Psychiatry 21: 259-262, 1988.
52. Chien C-P, Lin S-K, Jann ME, et al: Ethnic variation in the plasma level of clozapine and desmethylclozapine.
53. Szymanski S, Lieberman JA, Picou D, et al: A case report of cimetidine-induced clozapine toxicity. Journal of Clinical Psychiatry 52: 21-22, 1991.
54. Szegedi A, Wiesner J, and Hiemke C: Improved efficacy and fewer side effects under clozapine treatment after addition of fluvoxamine. Journal of Clinical Psychopharmacology 15: 141-143, 1995.
55. Eggert AE, Crismon ML, Dorson PG: Lack of effect of fluoxetine on plasma clozapine concentrations. Journal of Clinical Psychiatry 55: 454-455, 1994.
56. Centorrino F, Baldessarini RJ, Kando J, et al: Serum concentrations of clozapine and its major metabolites: Effects of cotreatment with fluoxetine or valproate. American Journal of Psychiatry 151: 123-125, 1994.
57. Tyson SC, Devane CL, and Risch SC: Pharmacokinetic interaction between risperidone and clozapine. American Journal of Psychiatry 152: 1401-1402, 1995.
58. Koreen AR, Lieberman JA, Kronig M, et al: Cross-tapering clozapine and risperidone. American Journal of Psychiatry 152: 1690, 1995.
59. Miller DD: Effect of phenytoin on plasma clozapine concentrations in two patients. Journal of Clinical Psychiatry 52: 23-25, 1991.
60. Tiihonen J, Vartiainen H, and Hakola P: Carbamazepine-induced changes in plasma levels of neuroleptics. Pharmacopsychiatry 28: 26-28, 1995.
61. Raitasuo V, Lehtovaara R, and Huttunen MO: Carbamazepine and plasma levels of clozapine. American Journal of Psychiatry 150: 169, 1993.
62. Finley P and Warner D: Potential impact of valproic acid therapy on clozapine disposition. Biological Psychiatry 36: 487-488, 1994.
63. Longo LP and Salzman C: Valproic acid effects on serum concentrations of clozapine and norclozapine. American Journal of Psychiatry 152: 650, 1995.
64. Haring C, Fleischhacker WW, Schett P, et al: Influence of patient-related variables on clozapine plasma levels. American Journal of Psychiatry 147: 1471-1475, 1990.
65. McEvoy J, Freudenreich O, McGee M, et al: Clozapine decreases smoking in patients with chronic schizophrenia. Biological Psychiatry 37: 550-552, 1995.
66. George TP, Sernyak MJ, Ziedonis DM, et al: Effects of clozapine on smoking in chronic schizophrenic outpatients. Journal of Clinical Psychiatry 56: 344-346, 1995.
67. Gerson SL, and Meltzer HY: Mechanism of clozapine-induced agranulocytosis. Drug Safety (suppl 1): 18-25, 1992.
68. Hasegawa M, Cola PA and Meltzer HY: Plasma clozapine and desmethylclozapine levels in clozapine-induced agranulocytosis. Neuropspychopharmacology 11: 45-46, 1994.
69. Centorrino F, Baldessarini RJ, Flood JG, et al: Relation of leukocyte counts during clozapine treatment to serum concentrations of clozapine and metabolites. American Journal of Psychiatry 152: 610-612, 1995.
70. Olesen OV, Thomsen K, Jensen PN, et al: Clozapine serum levels and side effects during steady state treatment of schizophrenic patients: a cross-sectional study. Psychopharmacology 117: 371-378, 1995.
71. Devinsky O, Honigfeld G, and Patin J: Clozapine-related seizures. Neurology 41: 369-371, 1991.
72. Simpson GM and Cooper TB: Clozapine plasma levels and convulsions. American Journal of Psychiatry 135: 99-100, 1978.
73. Haring C, Neudorfer C, Schwitzer J, et al: EEG alterations in patients treated with clozapine in relation to plasma levels. Psychopharmacology 114: 97-100, 1994.